Noscira's GSK3 inhibitor misses AD endpoint

Noscira S.A. (Madrid, Spain) said tideglusib missed the primary endpoint in the European Phase IIb ARGO trial in 306 patients with mild to moderate Alzheimer's disease (AD). The glycogen dependent kin...